Welcome Visitor Friday, November 22, 2024

Articles related to Jeff Conn


Vanderbilt IP licensed to IPO-prospect Neumora might earn VU millions
Vanderbilt IP licensed to IPO-prospect Neumora might earn VU millions

Scenario: VU could garner up to $422MM, as fight against neurospsych disorders, degenerative diseases advances.

Read More
Appello Pharma completes Series A to advance treatment of Parkinson's
Appello Pharma completes Series A to advance treatment of Parkinson's

[Updated] Less than three years into their mission, Deerfield, Mountain Group and founders press forward.

Read More
Drug-discovery linchpin PMI BioPharma Solutions hoists flag in Tennessee
Drug-discovery linchpin PMI BioPharma Solutions hoists flag in Tennessee

The word is just getting out about new entrant in Tennessee biopharm ecosystem.

Read More
LifeScienceTN: Drug discovery gets spotlight in venture-oriented event
LifeScienceTN: Drug discovery gets spotlight in venture-oriented event
Drug-discovery, partnerships and commercialization among conference highlights
Read More
VUMC scientists seek partners for neuro-drug discovery
VUMC scientists seek partners for neuro-drug discovery
Two pharmas are already aboard and other allies for accelerating drug development may be in-the-offing
Read More
BioMimetic CEO urges 'build on Bredesen's start', plus greater Vanderbilt role in life-sciences ventures
BioMimetic CEO urges 'build on Bredesen's start', plus greater Vanderbilt role in life-sciences ventures

Lynch cites workforce challenges and the need for more collaboration throughout the region as essential to lift Nashville from lower tier of life-science centers

Read More
VU's Conn advocates new models for drug discovery
VU's Conn advocates new models for drug discovery

Vanderbilt pharma program inches cautiously toward tech transfer, while key faculty member keeps firm hand on the tiller

Read More

Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: